HeartFlow, Inc. stock analysis
Want to see HTFL full AI Analyst Report?
HeartFlow, Inc. (HTFL) Stock Price & Analysis
HTFL Stock Chart & Stats
- Day’s Range
- $43.78 - $47.16
- 52-Week Range
- $20.13 - $60.66
- Previous Close
- $44.63
- Volume
- N/A
- Average Volume (3M)
- 1.72M
- Market Cap
- $3.92B
- Enterprise Value
- $4.20B
- Total Cash (Recent Filing)
- $167.74M
- Total Debt (Recent Filing)
- $25.93M
- Price to Earnings (P/E)
- ―
- Beta
- 1.35
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- -0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Account Growth
The raised revenue outlook and strong account activation trends indicate expanding adoption of HeartFlow’s platform. Sustained growth across FFRCT and Plaque can deepen the installed customer base, increase utilization over time, and support operating leverage as newer accounts mature.
Platform Expansion And Clinical Validation
Extending the platform from diagnosis into PCI planning broadens HeartFlow’s role in the cardiac-care workflow and increases its potential revenue opportunities. The Boston Scientific collaboration and supporting clinical evidence may strengthen adoption, physician confidence, and competitive differentiation.
Margin And Operating Leverage
Higher gross margins and declining operating expenses as a share of revenue show that growth is beginning to translate into improved economics. Continued volume leverage, automation, and product mix benefits could support further margin expansion as revenue scales toward management’s 85% target.
Bears Say
Persistent Operating Losses
HeartFlow remains substantially unprofitable despite improving revenue and non-GAAP results. Large operating losses consume resources that could otherwise fund expansion, and profitability must improve materially for the company to build durable earnings power rather than rely primarily on continued growth investment.
Continued Cash Burn
Negative operating and free cash flow means the business is not yet self-funding its operations and growth. Even with improved burn versus earlier periods, persistent cash consumption can increase financing dependence and constrain flexibility if the path to profitability takes longer than expected.
Delayed Cash Profitability And Pricing Pressure
The profitability target remains several years away, leaving execution dependent on continued growth, cost discipline, and adequate funding. Expected moderation in FFRCT pricing could also limit revenue quality and offset some benefits from adoption, making the transition to positive cash flow more difficult.
HeartFlow, Inc. News
HeartFlow: Buy Rating Reaffirmed as Long-Term Earnings Outlook and Revenue Projections Remain Intact Despite Minor EBITDA Adjustment
William Blair analyst Brandon Vazquez has maintained their bullish stance on HTFL stock, giving a Buy rating on August 14. Brandon Vazquez’s rating is based on the view that HeartFlow’s
HTFL FAQ
What was HeartFlow, Inc.’s price range in the past 12 months?
What is HeartFlow, Inc.’s market cap?
When is HeartFlow, Inc.’s upcoming earnings report date?
How were HeartFlow, Inc.’s earnings last quarter?
Is HeartFlow, Inc. overvalued?
Does HeartFlow, Inc. pay dividends?
What is HeartFlow, Inc.’s EPS estimate?
How many shares outstanding does HeartFlow, Inc. have?
What happened to HeartFlow, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HeartFlow, Inc.?
What is the TipRanks Smart Score and how is it calculated?
HeartFlow, Inc. Stock Smart Score
Company Description
HeartFlow, Inc.
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- John Farquhar
- Employees
- 843
- Website
- www.heartflow.com
- Address
- 135 Main Street, San Francisco, CA, 94105, US
HeartFlow, Inc. (HTFL) Earnings & Revenues
HTFL Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Revenue, case volumes, Plaque and FFRCT adoption, clinical evidence, gross margins, operating leverage and full-year guidance all improved, while the company reported a well-capitalized balance sheet and increased confidence in reaching cash flow profitability by mid-2028. The principal negative points were the remaining GAAP and non-GAAP operating losses, expected fourth-quarter seasonality, roughly flat sequential Plaque pricing in Q4 and moderation in FFRCT pricing trends beginning in 2027.
View all HTFL earnings summariesHTFL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 9 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 5 | 0 | 7 |








